Genetically engineered T-cells for adoptive immunotherapy.
Adaptive immunotherapy with T-cells is being evaluated as therapy for a number of malignancies and viral infections. Genetic modification of infused T-cells has been used for several years to track such cells, to redirect and augment the immune response towards tumors, and to provide a means of ablating infused T-cells should adverse effects occur. New strategies to target T-cells to tumors and to genetically modify them to make them resistant to tumor evasion mechanisms are being evaluated in preclinical models.
Pule
Martin
M
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
Bollard
Catherine M
CM
Heslop
Helen E
HE
D005818:Genetic Engineering; D006801:Humans; D016219:Immunotherapy, Adoptive; D013601:T-Lymphocytes / Q000276:immunology*